{
  "id": "6025e2641cb411341a0000bb",
  "type": "yesno",
  "question": "Can thiotepa be recommended for treatment of osteosarcoma?",
  "ideal_answer": "No. Thiotepa did not improve survival of patients with osteosarcoma and therefore can not be recommended for treatment of osteosarcoma.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31838406",
    "http://www.ncbi.nlm.nih.gov/pubmed/24672280"
  ],
  "snippets": [
    {
      "text": "CONCLUSION: Adjuvant HDTp failed to significantly improve OS and PFS in resectable relapsed osteosarcomas. Despite a trend of prolonged survival and an acceptable toxicity, thiotepa cannot be recommended.KEY MESSAGE: HDTp and autologous transplantation added to SCT did not improve OS and PFS in patients with resectable relapsed osteosarcomas. Despite a trend of prolonged survival, thiotepa cannot be recommended.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31838406",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusion. The use of HD thiotepa and ASCT is feasible in patients with relapsed osteosarcoma. A randomized study for recurrent osteosarcoma between standard salvage chemotherapy and high dose thiotepa with stem cell rescue is ongoing.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24672280",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}